Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib extended treatment protocol
NCT03229200Phase 4Active, not recruiting
- Sponsor
- Pharmacyclics
- Start
- May 2017
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 4 trial of ibrutinib in B cell lymphoma, non-Hodgkin lymphoma (NHL), B-cell leukemia (BCL), graft-versus-host disease (GVHD), solid tumor, sponsored by Pharmacyclics. Started May 2017; status: active, not recruiting.
02
Drugs
ibrutinib
03
Conditions
B cell lymphomanon-Hodgkin lymphoma (NHL)B-cell leukemia (BCL)graft-versus-host disease (GVHD)solid tumor
Beyond the preview
Go deeper on NCT03229200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03229200.